PHASE II moderated Expert Advisory Boards helped determine an optimized product TPP, TCP and clinical trial strategy. ​
PHASE II has recently managed a series of Strategy Development Advisory boards in the US, Europe and the Asia Pacific Regions– for a small biopharmaceutical company with products in phase 2 to support planning for phase 3 clinical trials. Agenda topics included consensus disease definition(s); defining unmet clinical needs; target patients & segmentation; TPP criteria per segment; AI prediction model for disease identification; inclusion/ exclusion criteria for future Phase 3 trials. Insights from their most important regions, were able to be consolidated into a robust all encompassing global strategy which they are now pursing.​
Contact us for further information on our approach to Advisory Board delivery
